This Blog Is Powered By Life Technology™. Visit Life Technology™ At www.lifetechnology.com Subscribe To This Blog Via Feedburner / Atom 1.0 / RSS 2.0.
Monday, November 9, 2020
New medication may treat underlying causes of hypertrophic cardiomyopathy
The new, investigational heart medication mavacamten may improve key structural abnormalities of obstructive hypertrophic cardiomyopathy, a condition characterized by thickened heart muscle that obstructs pumping of blood through the heart, according to research from the Phase 3 EXPLORER-HCM trial, to be presented at the American Heart Association's Scientific Sessions 2020.